---
document_datetime: 2023-09-21 19:31:52
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/namuscla-epar-all-authorised-presentations_en.pdf
document_name: namuscla-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.013155
conversion_datetime: 2025-12-27 16:45:21.945868
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ANNEX A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging    | Pack size    |
|------------------|-------------------|------------|-----------------------|---------------------------|------------------------|--------------|
| EU/1/18/1325/001 | Namuscla          | 167 mg     | Capsule, hard         | Oral use                  | blister (PVC/PVDC/Alu) | 30 capsules  |
| EU/1/18/1325/002 | Namuscla          | 167 mg     | Capsule, hard         | Oral use                  | blister (PVC/PVDC/Alu) | 50 capsules  |
| EU/1/18/1325/003 | Namuscla          | 167 mg     | Capsule, hard         | Oral use                  | blister (PVC/PVDC/Alu) | 100 capsules |
| EU/1/18/1325/004 | Namuscla          | 167 mg     | Capsule, hard         | Oral use                  | blister (PVC/PVDC/Alu) | 200 capsules |